Anti-CXCR4 in vitro and in vivo pre-clinical activity 2 Abstract Purpose: CXCR4 has been identified as a prognostic marker for acute myeloid leukemia (AML) and other malignancies. We describe the development and characterization of a fully human antibody to CXCR4 and its application for therapy of AML, non-Hodgkin's lymphoma (NHL), chronic lymphoid leukemia (CLL), and multiple myeloma (MM). Research.
Anti-CXCR4 in vitro and in vivo pre-clinical activity
Conclusions: BMS-936564/MDX-1338 is a potent CXCR4 antagonist which is efficacious as monotherapy in tumor bearing mice and is currently in Phase I for the treatment of relapsed/refractory AML, NHL, CLL, and MM.
Translational Relevance: Expression of CXCR4 has been identified as a prognostic indicator for acute myeloid leukemia (AML) and other malignancies, in which greater expression of CXCR4 correlates with disease severity. CXCR4
plays an important role in both homing and retention of leukemic or stem cells in the bone marrow and an antagonist of CXCR4 mobilizes these cells into the bloodstream. In addition to mobilization, a direct apoptotic effect of the antibody was discovered suggesting that direct killing may be a mechanism for tumor growth inhibition. These features, together with the fact that an antibody has a longer half life, may offer advantages over a small molecule. Consequently, clinical trials in relapsed/refractory AML, NHL, CLL, and MM are currently ongoing.
INTRODUCTION
CXCR4, also known as CD184, is a 7 transmembrane spanning protein consisting of an extra-cellular N-terminal tail and three extra-cellular loops. The intracellular carboxy terminus of CXCR4 is coupled to a heterotrimeric G-protein consisting of β and γ subunits and a pertussis toxin-sensitive Gi α subunit. 1 To date, only one ligand for CXCR4, CXCL12, also known as SDF-1 has been identified. 2, 3 CXCL12 binding to CXCR4 stimulates activation of phospholipase C and subsequently results in an elevation of cytosolic free calcium. Ligation of CXCR4 ultimately leads to induction of chemotaxis and migration. 4, 5 Anti-CXCR4 in vitro and in vivo pre-clinical activity found in various tissues with predominant expression on hematopoietic lineage cells including B and T cells, monocytes, macrophages, NK, and dendritic cells, as well as CD34 + bone marrow progenitor cells. 6 Low levels of CXCR4 are also expressed on endothelial and epithelial cells, astrocytes, and neurons. 7, 8 CXCL12 has been shown to induce endothelial cell migration and proliferation and together with VEGF were shown to enhance neoangiogenesis. 9 Over expression of CXCR4 has been found in 75% of cancers including leukemias, lymphomas, pancreatic, breast, ovarian, lung, prostate and colorectal tumors. Additionally, this pathway is implicated in stimulating the metastatic process in multiple neoplasms. 10 In clinical studies, CXCR4 has been associated with increased propensity for metastasis and decreased survival and was identified as a prognostic indicator for AML, breast, colorectal, non small cell lung, ovarian and pancreatic carcinoma in which greater expression of CXCR4 correlates with disease severity.
11,12,13, 14, 15, 16 Bone marrow stromal cells secrete CXCL12 and the interaction with CXCR4 is essential for homing and maintaining hematopoietic stem cells within the bone marrow microenvironment. 17 Leukemic cells express high levels of CXCR4, and the pathway plays a critical role in leukemic cell migration into the bone marrow which in turn, supports their growth and survival. CXCR4 is essential for metastatic spread to organs such as bone marrow where CXCL12 is Anti-CXCR4 in vitro and in vivo pre-clinical activity molecule CXCR4 antagonist, plerixofor (Mozobil) which was approved by the FDA for use in combination with granulocyte-colony stimulating factor for autologous transplants in NHL and MM patients. 18 In AML, CXCR4 is highly expressed on the CD34 + fraction of bone marrow cells. Lower levels of CXCR4 on AML cells correlate with a better prognosis resulting in a longer relapse free and overall survival. The lower CXCR4 receptor expression attenuates migration of primary AML cells toward CXCL12 expressed in the chemo-protected environment of the bone marrow. 19 In addition to AML, serum levels of CXCL12 are elevated in patients with multiple myeloma and CXCR4 expression increases in extramedullary plasmacytoma, a manifestation of an advanced stage of multiple myeloma. Furthermore, blockade of the CXCL12/CXCR4 axis attenuates tumor growth in MM tumor models. 20 In this report we describe the generation of a fully human monoclonal antibody specific for human CXCR4. MDX-1338 has low nM affinity for 
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Antibody generation
Mice from Medarex KM Anti-CXCR4 in vitro and in vivo pre-clinical activity 8 CXCL12. Spleen lysates were pooled and processed as described previously. 22 Using proprietary phage display procedures, Biosite generated antibody fragments (Fab library). Phage which bound to CXCR4 were selected on CXCR4 magnetic proteoliposomes (MPLs) 23 which were prepared from HEK293E cells expressing CXCR4. Phage binding to CXCL12 were selected using biotinylated-CXCL12.
Selected antigen reactive Fab were converted to full length IgG 4 (S228P) and reexpressed in CHO cells.
Functional characterization of CXCL12 and CXCR4
Serial dilutions of MDX-1338, anti-CXCL12 and control antibody were tested for blockade of 
Blockade of CXCL12-Induced Migration
The optimal concentration of CXCL12 for inducing Ramos migration was established to be 10 ng/mL (1.25 nM) while CEM cells were more sensitive to 
In Vitro Induction of Apoptosis
Because we observed robust in vivo activity, studies were undertaken to understand the mechanism of action of MDX-1338. A maximum of ~50% inhibition of Ramos cell proliferation was seen with 40 nM MDX-1338 treatment ( Figure 4A ) compared to isotype control. By comparison, AMD3100, a small molecule CXCR4 antagonist did not inhibit proliferation. A recently described peptide antagonist, BKT140, did inhibit proliferation however at much higher concentrations (100 μM).
Antibody-induced apoptosis was investigated using Ramos cells and MDX-1338 for 24 hours. For comparison, the small molecule CXCR4-antagonist, AMD3100 was investigated using 6 μM corresponding to a concentration which inhibited CXCL12-induced calcium flux and migration. (Table 1) .
MDX-1338 inhibits tumor growth of AML models.
To assess the antibody's efficacy in AML we used two cytarabine resistant mouse xenograft models, HL-60 and Nomo-1. The CXCR4 expression in each cell line was confirmed by FACS staining ( Figure 1A) . SCID mice containing established HL60 tumors were treated with MDX-1338 and on Day 27, the median tumor growth inhibition was 88% and 83% when compared to isotype and vehicle groups, respectively ( Figure 3B ).
Research. 
In the Nomo-1 model, the mice were dosed with MDX-1338 or cytarabine and monitored for 57 days. On day 34, the median tumor growth inhibition of MDX-1338 treated mice was significantly delayed by 88% compared to isotype or vehicle control ( Figure 3C ). As expected, Cytarabine did not inhibit tumor growth.
MDX-1338 inhibits tumor growth of MM models.
CXCR4+ myeloma cells, MOLP8 and JJN-3R, were tested for sensitivity to MDX-1338 in SCID xenograft tumor models. MOLP8 cells were implanted into SCID mice and the mice were treated with, 10 mg/kg/dose of MDX-1338 ±50 mg/kg lenalidomide or ±0.8 mg/kg bortezomib ( Figure 3D ). MDX-1338 significantly delayed mean tumor growth by 66% and 56% when compared to isotype control on Day 25 (last day when all mice in each cohort remained in the study). MOLP8 tumors were relatively resistant to lenalidomide and bortezomib and the efficacy of MDX-1338 was not improved when combined with either drug. At the end of study on day 42, 5 out of 8 mice remained in the MDX-1338 group while no mice remained in the isotype treated group. The bortezomib resistant, JJN3R cells were implanted into SCID mice and mice were dosed when the tumors were established. Median tumor growth over time is shown in Figure   3E . Neither lenalidomide nor bortezomib alone inhibited tumor growth while median tumor growth inhibition was 100% for mice treated with MDX-1338 on day 25 compared to mice treated with isotype. At the end of study, 4 out of 7 mice were tumor free in the MDX-1338 30 mg/kg group.
Discussion
Research.
on Anti-CXCR4 in vitro and in vivo pre-clinical activity unlikely that anti-tumor control is dependent on blockade of the CXCL12/CXCR4 axis. A direct effect of MDX-1338 was tested in a Ramos cell proliferation assay. CXCL12 has been implicated as an autocrine factor promoting cell growth and in a separate study CXCL12 siRNA inhibited BR5-1 growth.
26 27, Though the inhibition of growth was partial in our studies, we observed a dose-dependent inhibition of proliferation with anti-CXCR4 while AMD3100, and anti-CXCL12 antibody had no effect. Recently, a 14-residue polypeptide reported to be a specific CXCR4 antagonist (BKT140) was shown to inhibit proliferation of multiple myeloma cells. 28 It has been suggested that AMD3100 is a weak partial agonist while BKT140 acts as an inverse agonist. (Table 1) confirming that this mechanism is not restricted to one cell type.
Though MDX-1338 binds to healthy peripheral blood leukocytes, preliminary data from our AML trial has shown that the drug is well tolerated. To date, over 40 patients have been dosed up to 10mg/kg and we have not seen any adverse events associated with the antibody.
In vivo published data support that antagonists of CXCR4 are efficacious in AML and MM tumor models by enhancing the sensitivity of the tumors cells to chemotherapy. 37, 38 In contrast, in the studies presented here, we show that a statistically significant tumor growth inhibition was achieved when MDX-1338 was administered as monotherapy in AML and MM models. 36. Berndt C., Mopps B., Angermuller S., Gierschik P., Krammer P.H. CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4+ T cells. PNAS. 1998;95: 12556-61.
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CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Table Legends   Table 1 
